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Abstract
The promise of personalized cancer medicine cannot be fulfilled until we gain better understanding of the connections
between the genomic makeup of a patient’s tumor and its response to anticancer drugs. Several datasets that include both
pharmacologic profiles of cancer cell lines as well as their genomic alterations have been recently developed and
extensively analyzed. However, most analyses of these datasets assume that mutations in a gene will have the same
consequences regardless of their location. While this assumption might be correct in some cases, such analyses may miss
subtler, yet still relevant, effects mediated by mutations in specific protein regions. Here we study such perturbations by
separating effects of mutations in different protein functional regions (PFRs), including protein domains and intrinsically
disordered regions. Using this approach, we have been able to identify 171 novel associations between mutations in specific
PFRs and changes in the activity of 24 drugs that couldn’t be recovered by traditional gene-centric analyses. Our results
demonstrate how focusing on individual protein regions can provide novel insights into the mechanisms underlying the
drug sensitivity of cancer cell lines. Moreover, while these new correlations are identified using only data from cancer cell
lines, we have been able to validate some of our predictions using data from actual cancer patients. Our findings highlight
how gene-centric experiments (such as systematic knock-out or silencing of individual genes) are missing relevant effects
mediated by perturbations of specific protein regions. All the associations described here are available from http://www.
cancer3d.org.
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Introduction
With the body of genomic and pharmacologic data on cancer
growing exponentially, the main bottleneck to translate such
information into meaningful and clinically relevant hypothesis is
data analysis [1–3]. While numerous methods have been recently
applied to the analysis of such datasets [4] most of them,
particularly those dealing with mutation data [5], use a protein-
centric perspective, as they do not take into account the specific
position of the different mutations within a protein [6,7]. Such
approaches have been proven useful in many applications;
however, they cannot fully deal with situations in which different
mutations in the same protein have different effects depending on
which region of the protein is being altered [8]. This idea can be
easily explained by the fact that most proteins are modular,
consisting of several distinct domains and/or functional regions,
which we collectively call PFRs (protein functional regions) here.
For instance, a receptor tyrosine kinase, such as EGFR, has two
PFRs - an extracellular region, which is responsible for the
interaction with the ligand or with other receptors, and an
intracellular kinase domain, which in turn is responsible for the
phosphorylation of its substrates. A phenotype, such as the
response towards a drug, can be influenced by alterations of
proteins at the whole-protein level (changes in expression, deletion
or epigenetic silencing of a gene), but also changes, such as
mutations, modifying only the extracellular or the kinase domains.
More importantly, even though it is likely that each of the three
types of alterations (whole-protein, only in the extracellular region
or only in the kinase domain) will have different consequences [9],
only those involving the whole protein have been studied.
To explore how perturbations of specific PFRs in different
proteins might influence the sensitivity of cancer cell lines towards
specific drugs we developed a novel algorithm called e-Drug. This
algorithm analyses patterns of mutations in functional regions
within each protein in the human proteome and identifies those
associated with changes in the activity of anticancer drugs. Our
definition of PFRs includes protein domains, both those present in
Pfam database and those predicted to exist using our in-house
tools, and intrinsically disordered regions. Similar approaches
focusing on Pfam protein domains have been used previously to
study the molecular mechanisms underlying the pleiotropy of
certain genes, especially those related to Mendelian disorders
[10,11], and cancer [12–14]. In the context of the analysis of drug-
related data, PFRs have been mainly used to study phenomena
such as polypharmacology or the structural details underlying
interactions between drugs and domains [15,16]. However, to the
best of our knowledge, such PFR-centric analyses have ever been
used to study cancer pharmacogenomic datasets.
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Results
Analysis schema and overall results
The e-Drug analysis protocol introduced here is illustrated in
Fig. 1 on the example of the ERBB3 protein and the c-Met
inhibitor PF2341066. Some of the many functional relationships of
this protein include physical interactions (with EGFR, NRG1 and
JAK3) or phosphorylations (by CDK5 or ERBB3 itself). Each of
these relationships can be mapped to a specific PFR within
ERBB3. For example, the N-terminal EGF receptor domains
(shown in red in Fig. 1) mediate the interactions with EGFR and
NRG1, whereas ERBB3’s kinase domain (shown in blue in Fig. 1)
interacts with JAK3 and phosphorylates other ERBB3 molecules.
When using the protein level analysis, cell lines with mutations
in ERBB3 do not show any bias in the activity of PF2341066,
leading to a wrong conclusion that mutations in this protein do not
influence the sensitivity towards this drug. However, the PFR level
analysis shows that cell lines with mutations in the first receptor
domain are resistant to treatment with the PF2341066 inhibitor,
while those with mutations in any other PFRs of this protein, such
as the kinase domain of the second receptor domain, do not show
any specific behavior.
Following this protocol, we have identified 171 statistically
significant PFR-drug associations (p,0.05 in the comprehensive,
multistage significance analysis as described in the Methods
Section and S1 Supporting Material). The full list is provided in
the S1 Table and is available on-line from a newly developed
resource at http://cancer3d.org [17].
We have found some cases where two PFRs from the same
protein are associated with different drugs. For example, the
MSH6 protein contains 3 different PFRs associated with 3
different drugs (Fig. 2). Mutations in the N-terminal IDR are
associated with increased AEW541 activity, while mutations in
the connector (PF05188) and ATPase (PF00488) domains are
associated with higher Lapatinib and RAF265 activities, respec-
tively. Given that MSH6 has been recently shown to be involved
in pathways related to the repair of DNA-double-strand breaks
[18], the association identified here between mutations in
MSH6’s ATPase domain, as well as other PFRs in PAXIP1 or
TP53, and the activity of RAF265 suggest that the DNA-damage
response pathway might have a role in modulating the activity of
this drug.
Integration of CCLE with other molecular datasets
provides further insights into the role of individual PFRs
The best examples of the advantages of studying mutation
effects on individual PFRs are those where mutations in different
regions of the same protein are associated with the same drug but
in opposite directions. This is the case of PIK3CA and the IGF1R
inhibitor AEW541. Using e-Drug we found that mutations in the
p85 binding domain (PF02192) decrease the activity of the
AEW541 while mutations in the PIK accessory domain (PF00613)
are associated with increased activity of the same drug (Fig. 3).
Mutations in different regions of PIK3CA are known to be
oncogenic through different molecular mechanisms [19], which
could also explain the opposite effects in AEW541 sensitivity
observed for these two domains.
To find features that could explain the different responses to
AEW541 depending on the PIK3CA domain mutated, we used
proteomics data from The Cancer Proteome Atlas [20]. We
focused our analysis on IRS1 expression levels as well as Akt
phosphorylation status in the cell lines with mutations in the two
PIK3CA domains, because these proteins are immediately up and
downstream from PIK3CA, respectively (Fig. 3).
Cell lines with mutations in the PIK accessory domain did not
have changes in the phosphorylation levels of Akt at neither T308
(p.0.34) nor S473 (p.0.07), but did have higher IRS1
expression (p,0.05). These results agree with recent data
showing that the E545K mutation in PIK3CA enhances its
interaction with IRS1 [21]. Since IRS1 mediates the interaction
between IGF1R and PIK3CA, this increased interaction with
IRS1 (and therefore dependence on interaction with receptor
tyrosine kinases such as IGF1R) could explain why cell lines with
mutations in PF00613 are more sensitive to IGF1R inhibition
(Fig. 3).
On the other hand, cell lines with mutations in the p85
binding domain showed higher Akt phosphorylation levels at
both T308 (p,0.01) and S473 (p,0.02), and also had lower
IRS1 protein levels (p,0.01). Since Akt is one of the main
PIK3CA effectors, a possible interpretation of these results is that
cell lines with mutations in the p85-binding domain have
intrinsically active PIK3CA phosphorylation activity, regardless
of its interaction with receptor tyrosine kinases such as IGF1R.
In this scenario, inhibiting IGF1R with AEW541 would have
little effects, as these cells are already signaling downstream
towards Akt (Fig. 3).
Finally, given recent concerns about pharmacogenomic data
using cell lines [22] we compared these results to those obtained
from data on human tumors analyzed by TCPA (n= 2229). We
confirmed all the tumors with mutations in PF02192 have higher
levels of Akt phosphorylation at both T308 and S473. The same
samples also have lower IRS1 levels than those with no mutations
in PF00613 or no mutations at all. Tumor samples with mutations
in PF00613, on the other hand, have higher IRS1 levels and no
changes in Akt phosphorylation status.
Drug-PFR correlations predict success of cancer
treatment
Since we had been able to confirm the hypothetical molecular
mechanisms underlying the PFR-drug associations between
AEW541 and PIK3CA in tumor samples, we wondered whether
we could also predict survival of actual cancer patients using the
PFRs identified in the CCLE data. To that end, we used clinical
data from patients whose tumors have been analyzed by The
Cancer Genome Atlas (TCGA) groups [23] to find patients that
had been treated with drugs included in the CCLE. Since most of
these drugs are still under clinical research, there were sufficient
data only to analyze two types of drugs: Paclitaxel (n = 778) and
the topoisomerase inhibitors Irinotecan and Topotecan (n= 188).
We used genomic data of the patients to find those who had
mutations in PFRs that are associated to increased resistance
towards these drugs in our analysis (Fig. 4). While we found no
differences in patients treated with paclitaxel (p.0.9), patients that
Author Summary
There is increasing evidence that altering different func-
tional regions within the same protein can lead to
dramatically distinct phenotypes. Here we show how, by
focusing on individual regions instead of whole proteins,
we are able to identify novel correlations that predict the
activity of anticancer drugs. We have also used proteomic
data from both cancer cell lines and actual cancer patients
to explore the molecular mechanisms underlying some of
these region-drug associations. We finally show how
associations found between protein regions and drugs
using only data from cancer cell lines can predict the
survival of cancer patients.
Domain View of Drug Sensitivity
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had mutations in PFRs associated with resistance to Topoisom-
erase inhibitors had worse outcomes (p,0.01) than those with
mutations in other regions of the same proteins or no mutations in
these proteins at all. Interestingly, the mutation status of the whole
proteins that contain the associated PFRs cannot predict the
outcome of the patients (p.0.9), suggesting that only mutations in
the specific PFRs, but not in other regions of the same proteins,
confer resistance to topoisomerase inhibitors.
Fig. 1. Analysis at the functional region level allows us to gain novel insights from pharmacogenomics data. (a, b) Mapping of the
different ERBB3 functions to specific regions of the protein. Each functional relationship can be associated to a specific domain or intrinsically
disordered region in ERBB3. For example, EGF receptor domains (red boxes in (b)) mediate physical interactions between ERBB3 and EGFR and NRG1
(red edges in (a)). (c) Methods focusing at the whole-protein level can not find any association between ERBB3 mutations and the activity of
PF2341066. (d) Mutations altering specifically the N-terminal EGF receptor are associated to lower drug activity. (e) Mutations affecting another PFR in
ERBB3, its kinase domain, and that, thus, are mainly affecting other functional regions, are not associated to any changes in drug activity. (f), Venn
diagram showing the different thresholds that we have established in order to minimize false positives. We only kept PFRs with (I) p,0.001 when
compared to cell lines with no mutation in the protein, (II) p,0.05 when compared to cell lines with mutations in other regions of the same protein
and (III) with p.0.01 at the protein level.
doi:10.1371/journal.pcbi.1004024.g001
Domain View of Drug Sensitivity
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Proteins and PFRs associated with drugs do not usually
overlap with drug targets
One of the possible mechanisms for a PFR to be associated with
differential drug activity is that the protein itself directly interacts
with the drug of interest. To explore this hypothesis, we compared
the set of proteins associated with each drug at both whole-protein
and individual PFR levels, to the set of drug targets as identified by
the STITCH database [24]. Of the 19 drugs that had at least one
known target, only AZD6244 had its associated proteins and PFRs
enriched with its targets, as mutations in two of the five genes
known to code for proteins interacting directly with the drug,
BRAF and KRAS, are also associated with differential activity for
this drug (p,0.005). Expanding our search by varying the
STITCH interaction score, including proteins that interact with
compounds that have similar structures to the drugs included in
the analysis (Tanimoto score.0.70) or to proteins interacting with
the drug targets also did not show any statistically significant
associations (S4 Fig.).
Gene set enrichment analysis of PFRs and proteins that
correlate with drug activity reveals common functions
We did a gene set enrichment analysis using GO annotations
downloaded from Uniprot to understand the shared functions and
relationships of the proteins and regions associated with changes in
drug activity, (Fig. 5). Several groups of GO terms identified in this
analysis, such as those related to signaling cascades (extracellular
and intracellular signaling), signal transduction (kinase activity or
protein phosphorylation), or protein binding, suggest that these
genes might be involved in either the same pathways as the actual
drug targets or similar pathways that might have some level of
redundancy. Other GO terms, such as apoptosis, regulation of cell
proliferation, or response to hypoxia, are functions known to play
a role in drug resistance and carcinogenic potential of cells.
Another group of GO terms identified in our analysis are those
associated with the cytoskeleton. Given that most of the drugs
analyzed in this study (17 out of 24) are kinase inhibitors, this was
an unexpected observation. However, there is some evidence of
the relationship between cytoskeleton proteins and the activity of
kinase inhibitors in the literature. For example, many receptor
tyrosine kinases, such as EGFR, HER2, IGF1R, or FGFR,
undergo internalization upon ligand binding. Moreover, interac-
tions between Erlotinib and MYO2 or MYH9 have been
described, and a MYH9 inhibitor synergizes with EGFR inhibitors
to induce apoptosis in cells carrying the drug-resistant mutation
T790M [25].
Discussion
Identifying biological features that correlate with the activity of
anticancer drugs has been the subject of a significant and growing
research focus in recent years. However, most of these efforts do
not take into account the modular nature of proteins and focus on
perturbations at the whole-protein level. Such analyses are likely to
miss cases in which the location of the mutation within the protein
influences its effects. Here we have described what is, to the best of
our knowledge, the first systematic analysis of drug activity
associations that distinguishes between different functional regions
Fig. 2. Perturbations of different regions in the same protein can have different drug effects. (a) Missense mutations in different PFRs of
MSH6 lead to increased sensitivity towards three different drugs: AEW541, RAF5 and Lapatinib. The protein level analysis on the other hand reveals a
potential association with Erlotinib (shown in blue). This highlights the complementarity between protein and PFR-centric approaches.
doi:10.1371/journal.pcbi.1004024.g002
Domain View of Drug Sensitivity
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within proteins. We have shown that by focusing on specific PFRs
we can find 171 associations between mutations in specific protein
regions and changes in the activity of anticancer drugs. These
associations could not have been identified by protein-centric
approaches, as cell lines carrying mutations in other PFRs of the
same protein (i.e. perturbing regions that mediate other functions)
are not associated with any, with different or sometimes the
opposite drug phenotypes.
Cases in which the same gene is associated with different drugs
through different PFRs, as in the case of MSH6 and the kinase
inhibitors Erlotinib, AEW541, Lapatinib, and RAF265 can
provide insights into the mechanisms of the drug pleiotropy of a
given gene, aiding in further experiments. A variation of this
category is the association between PIK3CA and the AEW541,
where mutations in different PFRs can have opposing effects in
terms of the activity of the drug.
We have also shown the practical value of the PFR-drug
associations discovered here on the independent data from the
TCGA consortium. Specifically, we have shown that patients from
the TCGA harboring mutations in regions associated with
resistance to the drugs used to treat them have lower survival rates
than patients with mutations in the very same genes but in regions
not showing any association to the activity of such drugs. This result
not only provides evidence to the significance of our approach, but it
also argues in favor of the value of drug activity data collected using
cell lines (at least in the case of the CCLE), an issue that has recently
drawn significant attention [22] and that will probably require
substantial work in the near future in order to be solved.
Fig. 3. Using complimentary datasets to validate some of the predictions by e-Drug. (a) Missense mutations in PIK3CA can have opposite
effects in terms of AEW541 activity depending on the PFR affected. Mutations in the p85-binding and PIK accessory domains are associated with
lower and higher drug activities respectively (upper panel). By integrating our analysis with proteomics data from TCPA we have been able to
propose a mechanism for that. It appears that IRS1 protein expression is lower in cells with p85-binding mutations, but higher in those with PIK
mutations (second panel). Moreover, Akt1 phosphorylation levels are higher in cell lines with p85-binding domain mutations (two lower panels). (b)
Proposed mechanisms for the two PFR-AEW541 associations. AEW541 inhibits the kinase domain of IGF1R (upper blue protein). In those cell lines
with mutations in the PIK domain of PIK3CA (shown in blue PIK3CA’s structure), there is a gain of interaction between this protein and IRS1 (I). This
will likely increase the signaling through IGF1R (II), explaining why cell lines with mutations in this domain are more sensitive to the inhibition of this
receptor. On the other hand, cell lines with mutations in the p85-binding domain (shown in red in PIK3CA’s structure) have lower IRS1 expression and
higher AKT1 phosphorylation levels. Together, this suggests that PIK3CA is active in this cell lines independently of its interaction with extracellular
receptors, signaling directly downstream towards AKT1 (III). This would explain why these cells are resistant to AEW541.
doi:10.1371/journal.pcbi.1004024.g003
Domain View of Drug Sensitivity
PLOS Computational Biology | www.ploscompbiol.org 5 January 2015 | Volume 11 | Issue 1 | e1004024
Another interesting result of the analysis presented here is that
the proteins identified in our analysis as modulating sensitivity of
cancer cells to drugs, are distinct from the actual targets of these
drugs nor interact directly with them. This observation suggests
that these genes modify drug activity through indirect interactions.
For example, mutations in genes related to the cytoskeleton (a
subset enriched in the genes identified in our analysis) might alter
the potency of kinase inhibitors by changing the trafficking pattern
of receptor tyrosine kinases. This is one of the most unexpected
findings in our analysis. While more analyses and direct
experimental verifications of these correlations are needed, such
relations may suggest targets for therapies sensitizing cancer cells
to chemotherapy with specific drugs.
Overall, this work expands the number of correlations between
cancer somatic mutations and drug activity, thus increasing the
information we can extract from every dataset. Focusing on PFRs,
corresponding to protein domains or IDRs, provides better
statistical results than analysis of individual mutations and allows
to identify correlations in cases where different effects cancel out
and thus are missed on the whole gene analysis level. At the same
time, it provides more details about the mechanism of the drug
resistance than the analysis on the gene level. Increasing the
number and details of features that predict the activity of
anticancer drugs has important consequences in the field of
personalized medicine, as it increases accuracy in stratifying
patients into groups that require different treatment regiments and
can suggest drug combinations as exemplified for EGFR and
MYH9.
One interesting direction of work that we have not been able to
address refers to the interaction between multiple drug activity
modifiers. Now that we have been able to extend the catalog of
alterations that alter a cell’s sensitivity towards a drug using our
PFR-centric approach, what happens when there are multiple
such alterations in the same cell line or patient? Do they cancel
each other if they have opposite effects? Do they synergize if they
point towards the same direction? Most attempts to answer these
challenging questions are based on machine learning approaches
[5] which, given the multidimensional nature of the problem,
seems to be the most natural approach. However, simple methods
based on naively counting the presence or absence of specific
alterations, such as our own analysis of TCGA clinical data for
Irinotecan and Topotecan presented here or analyses based on
synthetic lethal interaction networks [4], seem to also have some
predicting power. Regardless of the specific approach, these are
questions that will need to be answered in order to achieve the
promise of personalized medicine.
Another generalization of our results is that data obtained
using gene knockouts, silencing RNAs, or other technologies that
completely abolish the activity of individual proteins might miss
more subtle effects caused by modifications of specific PFRs.
Finally, we would like to emphasize that, just like the analyses at
the protein level is not limited to the identification of features that
correlate with drug activity, the analysis of PFR perturbations can
be useful when looking for features associated with any
phenotype.
Materials and Methods
Cell line mutations
We have used the CCLE dataset, which includes the mutation
profiles of 1,668 genes in 906 human cancer cell lines and drug
activity data for 24 different anticancer compounds. We focused
our analysis on missense mutations, as truncating mutations can
sometimes be misleading when performing the analysis in terms of
functional regions. For example, when analyzing a protein that
contains two different domains, if a truncating mutation happens
in the first domain, it is not obvious whether the functional
consequences of the mutation are caused by the fact that the first
domain is altered or that the second domain is missing. We
mapped the missense mutations reported by CCLE from their
genomic coordinates to every protein coding isoform from
ENSEMBL using the Variant Effect Predictor tool [26]. From
the original 42,603 genomic-point mutations in 1,668 genes, we
obtained 156,817 protein missense mutations in 9,311 proteins.
Fig. 4. PFR perturbations identified using data from cell lines predict the survival of patients treated with Irinotecan. (a) Proteins with
PFR associated to Irinotecan resistance can not be used to successfully stratify cancer patients treated with this drug, as there are no differences
between patients with mutations in such proteins (gray) and those without them (black) (b) Specific PFR in these proteins do predict the outcome of
cancer patients. Patients with mutations altering the PFRs found using CCLE (red) have worse outcomes that those with mutations in other regions of
the same protein (green) or no mutations (black).
doi:10.1371/journal.pcbi.1004024.g004
Domain View of Drug Sensitivity
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Drug activity data
The CCLE contains data on the drug activity of 24 different
compounds in 479 cell lines from 8-point dose-response curves.
These curves are adjusted to a logistical-sigmoidal function and
described by 4 different variables: the maximal effect level (Amax),
the drug concentration at half-maximal activity of the compound
(EC50), the concentration at which the drug response reached an
absolute inhibition of 50% (IC50), and the activity area, which is
the area above the dose-response curve. In our analysis we have
used only the activity area because, according to the CCLE, it
captures simultaneously both variables of drug activity: its efficacy
and its potency.
Protein functional regions
We defined protein functional regions as domains or intrinsi-
cally disordered regions. We decided to include intrinsically
disordered regions because these can also contain important
functional regions such as phosphorylation sites or regions that
regulate or mediate protein interactions [27]. To identify protein
domains, we retrieved, for each protein isoform, annotated Pfam
domains from ENSEMBL. We have also included a set of 1,300
novel potential domains identified by AIDA, an algorithm based
on iterative recognition of domains by homology recognition
algorithms with various sensitivities [28]. We used Foldindex [29]
to predict intrinsically disordered regions for each protein,
including in our analysis those regions with a predicted unfolded
score below –0.1.
Finally, we mapped the different mutations of each cell line to
these protein features, giving us a total of 30,798 altered regions in
906 cell lines. These regions are divided into 19,918 Pfam domains
and 10,880 intrinsically disordered regions. Note that the features
can overlap, as the predictions were performed independently and
there is no reason why, for example, an intrinsically unfolded
region cannot overlap with (or even be located within) a Pfam
domain. Note also that these numbers refer to PFRs in all known
protein isoforms according to ENSEMBL v72. While the results
for all these PFR-Drug pairs can be browsed at http://www.
cancer3d.org [17], in this manuscript we only discuss results
obtained for the largest isoform of each protein (S1 Fig.). A similar
protocol to assign protein functional regions was used in our
previous publication on identifying domain cancer drivers [13].
Identification of PFR perturbations correlating with drug
activity
As explained above, e-Drug looks for PFRs that, when mutated,
correlate with drug activity of the different drugs. We divided the
cell lines into those that have a coding missense mutation in the
region being studied and those that do not. We then performed a
Fig. 5. Enrichment map of the proteins associated with differential drug activity at both, whole-protein and individual region
levels. We performed a gene-set enrichment analysis by comparing Gene Ontology (GO) annotations of the 316 proteins associated with different
drugs at both levels of resolution (whole-protein and individual PFRs) against the whole human genome. All the GO terms identified here showed an
enrichment in the biomarker group, and most of them relate to pathways and functions associated with carcinogenesis, metastasis, and drug
resistance, such as regulation of cell proliferation, kinase activity, cell migration, cell adhesion, MAPK cascade, or response to hypoxia. In the figure,
GO terms are connected when they are related according to the gene ontology.
doi:10.1371/journal.pcbi.1004024.g005
Domain View of Drug Sensitivity
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Wilcoxon test comparing the drug activity of each compound in
the two groups and kept those with a p-value below 0.01. Finally,
for those gene regions associated to a certain drug, the activity of
the cell lines mutated in the region of interest was compared to the
activity of cell lines mutated in other regions of the gene. By doing
this, regions that are significantly different from the rest of the gene
were identified. In this case, since the number of cell lines in both
groups is lower and fewer tests were performed, a significance
threshold of 0.05 instead of 0.01 was established. We considered as
true positives those PFR that passed both thresholds and that are
not in proteins that show an association (p,0.01) with the same
drug at the whole-protein level (S1 Fig.). Note that the analysis is
performed independently for each PFR. In the case that a protein
contains two overlapping regions, e-Drug will handle each one of
them independently and return their corresponding results.
Statistical significance analysis
One of the problems that arise when analyzing PFRs instead of
whole proteins is that the statistical power of the sample decreases
significantly, as (I) there are less cell lines with mutations in the
individual regions and (II) the number of correlations being tested
increases, making multiple-testing corrections more stringent. To
overcome these limitations and decrease the number of false positives
among our associations we require three different thresholds for an
association to be considered positive (see Fig. 1 and S1–S3 Figs.). First,
the p value of comparing the activity of the drugs between cell lines
with mutations in the PFR against those without them has to be below
0.01. This left us with 350 potential PFR-drug pairs identified in the
CCLE data. Then, we repeated the analysis at the protein level and
removed all the pairs that were also identified there (p,0.01, n=102,
Fig. 1f). Finally, for the remaining 248 pairs, we compared the drug
activity of the cell lines with mutations in the PFR against cell lines
with mutations in other regions of the same protein.
Protein expression data from TCPA
Expression data for 461 different proteins in 93 cancer cell lines
was downloaded from the TCPA website on 12/11/2013. Cell
line names used in TCPA were manually mapped to CCLE when
automated mapping was not possible.
In order to find proteins with altered expression or phosphor-
ylation levels in cell lines with mutations in PFRs of interest cell
lines, we grouped them according to the mutation status of such
PFRs and compared the expression levels in each group using a
Wilcoxon test. To find proteins whose expression correlated with
the activity of anticancer drugs we performed a Pearson
correlation test using R.
TCGA survival analysis
We have downloaded both, clinical and mutation data, for the
3,205 tumors described in the pan-cancer analysis of the TCGA.
We then filtered out data from patients that had not been treated
with any of the drugs included in the CCLE. Since most drugs
included in the CCLE are still in under clinical research, we only
had enough patients to analyze 2 different drugs: paclitaxel
(n = 778) and Irinotecan (n= 58). Each of these subsets of patients
have then been classified in 3 groups: those that have a mutation in
a PFR that, according to our analysis, increases resistance to the
drug used to treat them, those with mutations in other regions of
the same genes and those with no mutations in these genes.
We have limited our analysis to gene-regions associated with
lower drug activity because there are more such regions as
compared to regions associated with increased activity. As a result
very few patients in the TCGA dataset carry mutations in the
former type of regions and have been treated with the matching
drug. The survival analysis has been performed using the
‘‘Survival’’ package for R.
Protein–drug interaction data
It would be natural to expect that proteins that are associated
with drug phenotypes might be enriched in either drug targets or
their partners. To test this hypothesis, we downloaded the
STITCH database that contains information on protein–chemical
interactions. We then retrieved for each drug its known protein
interactions and compared the overlap of proteins on this list with
the proteins that showed an association with that same drug
according to our analysis with the Fisher test. We performed the
analysis using three different thresholds for the protein-drug
interaction score as reported in STITCH: 700, 800 and 900. We
also extended the analysis to (a) proteins interacting with drug
targets (according to either HPRD, BioGRID, MINT, or DiP) and
to (b) proteins that bind chemicals with a similar structure. We
defined these drug-like chemicals as those that have a Tanimoto
2D similarity score with the drug over 0.70. We calculated the
Tanimoto scores with the R package RCDK.
Supporting Information
S1 Fig. Distribution of the p values for all the pairs
considered for analysis. (a) When taking into account all the
protein isoforms expressed in each gene there are 739,152 possible
PFR-Drug pairs (blue region). In order to limit the number of regions
considered for the study we only considered PFRs located in the
largest isoform of each gene, leaving us with 202,417 possible pairs
(green region). However, only 99,758 had at least 2 mutations in
CCLE, which is the minimum number that we considered to start the
analysis (red circle). (b) Distribution of p values for all the analyzed
pairs. As expected, most pairs have a p value around 1, whereas only
405 are below the 0.01 threshold (vertical red dashed line). (c) The
distribution of mutations across the different PFR-Drug pairs follows a
power-like distribution, as most pairs have less than 20 mutations, but
a few pairs have over 150. (d) Relationship between number of
mutations in each pair and the observed p value. As expected, as the
number of mutations in each PFR-Drug pair is not correlated with the
number of mutations, however, there are no pairs with p values,0.01
(horizontal red dashed line) and less than three mutations.
(TIF)
S2 Fig. Protein functional regions within genes that are
also statistically significant are considered false posi-
tives. (a) Cell lines with mutations in the kinase domain of PRKG2
(between red dashed lines) show similar sensitivity towards 17-AAG
than cell lines with mutations in the rest of the protein. (b) While
there cell lines with mutations in the Kinase domain of PRKG2
show statistically significant lower 17-AAG activity (p,0.004), the
signal is also preserved (p,2-e6) at the whole gene level. This
suggests that this PFR is associated to this drug because it belongs to
PRKG2, not because there is something specific to the PFR.
(TIF)
S3 Fig. Protein regions that show differences when
compared to the rest of the protein are considered true
positives. (a) The intrinsically unstructured region (IUR)
between positions 334 and 699 (red dashed lines) in AFF4 is
associated with increased sensitivity towards the MEK inhibitor
PD-0325901. (b) The difference is statistically significant not only
when compared to cell lines with no mutations in AFF4 (p,0.003),
but also when compared to cell lines with mutations in other
regions of the same protein (p,0.002).
(TIF)
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S4 Fig. Drug-PFR containing proteins do not usually
interact with the drug or the drug’s targets. We checked
the overlap between PFR-containing proteins and each drug’s
targets (top panel) or proteins interacting with them (second panel
from the top). Only PFRs associated with AZD6244 were enriched
in drug targets (p,0.005, horizontal red dashed line). Extending
the search to chemical matter with similar structure to that of each
drug (Tanimoto score .70) yielded similar results (two bottom
panels).
(TIF)
S1 Table PFR-Drug associations and links to Cancer3D.
(XLS)
S1 Supporting Material Extended analyses and support-
ing figures. This file contains extended details about the p-values
distribution, the different p-value thresholds used in our analysis,
information about the protein-drug experiment as well as S1–S4
Figs.
(DOCX)
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